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Background: Intravenous artesunate (IV AS) is the present treatment of choice for severe malaria, but development
of artemisinin resistance indicates that a further agent will be needed. Methylene blue (MB) is an approved human
agent for IV and oral use, and is already being investigated for oral treatment of uncomplicated malaria. To initiate
investigation of IV MB for severe malaria, the efficacy of IV MB was compared to IV AS and to their combination in
rat and non-human primate malaria models.
Methods: IV MB was compared to IV AS and to their combination in the Plasmodium berghei-infected rat, a self-curing
model; the Plasmodium falciparum-infected Aotus monkey, a fatal model; and the Plasmodium cynomolgi-infected
rhesus monkey, a fatal model. Key endpoints were clearance of all parasites from the blood and cure (clearance without
recrudescence).
Results: In rats, the minimal dose of individual drugs and their combination that cleared parasites from all animals was
20 mg IV MB/kg/day, 60 mg IV AS/kg/day and 10 mg IV MB/kg/day plus 30 mg IV AS/kg/day. In Aotus, 8 mg IV MB/kg/
day and 8 mg IV AS/kg/day each cured two of three monkeys by one day after therapy, and the third monkey in each
group was cured two days later. The combination of both drugs did not result in superior efficacy. In rhesus, 8 mg IV
MB/kg/day and 8 mg IV AS/kg/day performed comparably: parasite clearance occurred by day 3 of therapy, although
only one of four animals in each dose group cured. Eight mg/kg/day of both drugs in combination was 100%
successful: all four of four animals cured.
Conclusions: In each of the three animal models, the efficacy of IV MB was approximately equal to that of standard of
care IV AS. In the rat and rhesus models, the combination was more effective than either single agent. This preclinical
data suggests that IV MB, alone or in combination with IV AS, is effective against Plasmodium spp. and can be
evaluated in severe malaria models.
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Severe malaria is a medical emergency and requires par-
enteral, preferably intravenous (IV), treatment. Even
with the classic standard of care IV quinine, mortality is
approximately 10 to 20% and generally occurs within
two to five days [1,2]. The new treatment of choice is IV
artesunate (AS), which reduced mortality compared with
quinine in two large Phase III trials [1,2]. Although ini-
tial IV treatment for approximately three days kills the* Correspondence: jbe9320457@aol.com
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not eliminate all parasites from the body. Once the pa-
tient is able to receive oral treatment, cure (elimination
of all parasites to prevent recrudescence) is accom-
plished by administration of longer half-life oral agents.
Oral artemisinin combinations are now the standard
of care worldwide for uncomplicated malaria, and early
reports of clinical resistance to AS are emerging from
Cambodia [3,4]. The development of resistance to arte-
misinins indicates that another agent in addition to IV
AS and IV quinine will be needed for initial treatment of
severe malaria.d. This is an Open Access article distributed under the terms of the Creative
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methaemoglobinaemia. MB has been investigated in vitro
and as an oral anti-malarial agent in the clinic. The bio-
chemical mechanism of MB’s approved use is to reduce
oxidized haemoglobin (methaemoglobin) back to haemo-
globin, and it is hypothesized that MB kills Plasmodium
spp via an increase in oxidants [5]. In vitro, MB is active
against both chloroquine-sensitive and chloroquine-
resistant parasites [6]. Oral MB was tested for treatment
of uncomplicated malaria in a region of chloroquine re-
sistance in Burkina Faso (37% early treatment failures with
chloroquine). Although MB at a dose of 4 mg/kg/day for
three days in combination with chloroquine was ineffect-
ive (29% early treatment failures [7]), a higher dose of MB,
12 mg/kg twice a day for three days, with chloroquine was
effective: there were no early treatment failures [8]. A dose
of MB at 10 mg/kg twice a day for three days was then
evaluated in combination with AS or with amodiaquine.
Both MB-plus-AS and MB-plus-amodiaquine were effect-
ive initially: there were no early treatment failures in either
group. Recrudescence was seen after MB plus AS but
not after MB plus amodiaquine [9]. These data are rea-
sonable given that the half-life of MB in humans is 15–19
hours [10], which means that MB needs to be partnered
with a long half-life drug such as amodiaquine to prevent
recrudescences.
The focus of clinical work to date with MB is on the
oral treatment of uncomplicated malaria. To initiate the
investigation of IV MB for severe malaria, the efficacy of
IV MB was compared to IV AS and to their combination




Artesunic acid (AS: Knoll AG, BASF Pharmaceuticals)
was formulated as an AS-lysine salt by dissolving AS in
5% of a DL-2,6-diaminohexanoic acid (DL-lysine) solu-
tion. MB salt was purchased from Aldrich Chemical Co
(Milwaukee, WI, USA). L-lysine (monohydrochloride),
which was used as control agent, and DL-lysine were ob-
tained from Sigma Chemical Co (Pittsburgh, PA, USA).
Animals and parasites
Groups of six to ten seven-week old Spraque-Dawley rats
were inoculated with a rat-adapted strain of Plasmodium
berghei ANKA as described previously [11]. Plasmodium
berghei is a self-curing parasite in rats: parasitaemia spon-
taneously diminishes beginning approximately day 12 after
inoculation.
Study design
First, each drug (IV AS or IV MB) was administered singly
using a sequential dose-escalation design. Each successivegroup of rats was administered a higher dose of drug until
the maximum tolerated dose (MTD) was achieved. The
MTD was defined as the highest dose that did not cause
death in any animals. Then, combinations of MB and AS
were administered again until the MTD was achieved. In
the combination experiments, IV AS was injected first
followed immediately by MB.
Study procedures
On study day 1, rats were inoculated intraperitoneally
with cryopreserved P. berghei-infected rat blood. When
parasitaemia was >4% on day 6, treatment was adminis-
tered daily for three days. Post-treatment, parasitaemia
was evaluated via tail-blood sampling at zero, three, five,
eight, and 12 hours on day 6; zero, three and six hours
on day 7 and 8; and daily from day 9 to day 12. The ex-
periments were performed in 2004.
Efficacy parameters and analysis
Determination of parasitaemia
Thin smears were examined under oil at 1,000× magnifi-
cation. Parasitaemia was calculated using the formula:
parasitaemia (%) = [number of infected red blood cells/
(number of infected red blood cells + number of non-
infected red blood cells)] × 100. A negative smear was
defined as the failure to observe a parasite after examin-
ation of 10,000 red blood cells (i.e., <0.01% parasitaemia).
Parasite clearance was defined as a negative blood
smear by day 12. Day 12 was taken as the end of the
time period during which clearance could be demon-
strated since in this model, the animals begin to self-
cure their infection on approximately this day [12]. The
parasite clearance time was defined as the time between
the beginning of dosing and the first negative blood
smear.




AS was purchased from Guilin #2 Pharmaceutical Fac-
tory, Guangxi, China. MB salt (3,7-Bis (dimethylamino)
phenthiazin-5-ium chloride) was purchased from Aldrich
Chemical Co (Milwaukee, WI, USA) and dissolved in 0.9%
sodium chloride.
Animals and parasites
Data were obtained from male and female laboratory-
bred Aotus lemurinus lemurinus monkeys Karyotype
VIII and IX [13], weight 692–1,345 g. The animals were
housed at Gorgas Memorial Institute of Health Studies
(ICGES) in Panama, and cared and maintained as de-
scribed elsewhere [14].
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using methods patterned after Schmidt [15]. Each parasite
inoculum contained 5 × 106 Plasmodium falciparum-par-
asitized erythrocytes (FVO strain) in a volume of 1.0 mL.
Non-splenectomized monkeys were used in these experi-
ments. Plasmodium falciparum (FVO strain) is generally
fatal in Aotus. In model development, of 293 monkeys that
were infected and untreated, 149 (50%) died within
15 days, 84 (29%) died within 30 days, and only 33 (11%)
self-cured [15].
Study design
For the first study, infected monkeys were randomly
assigned to four dosage groups: MB 0 mg/kg/day × three
days (MB0 - non drug treated control), MB 8 mg/kg/
day × three days (MB8), MB 16 mg/kg/day × three days
(MB16), MB 24 mg/kg/day × three days (MB24). There
was one monkey in the MB0 group and two monkeys in
each of the three experimental groups.
For the second study, infected monkeys were ran-
domly assigned to five dosage groups: MB0, MB 4 mg/
kg/day × three days plus AS 4 mg/kg/day × three days
(MB4 plus AS4), MB 8 mg/kg/day × three days (MB8),
AS 8 mg/kg/day × three days (AS8), MB 8 mg/kg/day ×
three days plus AS 8 mg/kg/day × three days (MB8 plus
AS8). There were two monkeys in the MB0 group and
three monkeys in each of the four experimental groups.
Study procedures
Blood smears were performed daily beginning four days
after parasite inoculation. Treatment was initiated when
the cohort’s parasitaemia level reached an aggregate
mean treatment threshold of approximately 50,000/mm3
[1%]. Treatment was given as a single IV injection of the
designated drug or immediate sequential injection of
both drugs in a combination once daily for three con-
secutive days. The experiments were performed in 2005.
Endpoints
Parasite counts were done by the Earle and Perez method
[16], using daily Giemsa-stained thick blood smears ob-
tained from a prick in the marginal ear vein.
Response to treatment was categorized as no effect, sup-
pression without clearance, clearance and recrudescence,
or clearance and cure. The day of clearance was defined as
the first of three consecutive days in which the thick blood
films were parasite negative. Suppression was defined as a
transient decrease in parasite density post-treatment with-
out clearance [17]. Animals that cleared parasitaemia were
followed for recrudescence with daily blood sampling for
parasite determinations until the end of the experiment
on day 24 (first experiment) or daily blood sampling until
day 32 then biweekly blood sampling until the end of the
experiment on day 105 (second experiment). The day ofrecrudescence was the first of three consecutive days of
positive thick blood films after a period of clearance. Ani-
mals that cleared and did not recrudesce by the end of the
experiment were considered cures.
Rhesus experiments
Drugs and chemicals
AS was purchased from Guilin #2 Pharmaceutical Factory,
Guangxi, China. For cohort 1, AS was dissolved as a 5%
solution in sodium bicarbonate and administered without
further dilution. In cohort 2, AS was dissolved as a 5%
solution in sodium bicarbonate then diluted with five vol-
umes of 5%-dextrose-in-water before being administered.
MB salt (3,7-Bis (dimethylamino) phenthiazin-5-ium
chloride) was purchased as a 1% solution (American Re-
agent Laboratories Inc, Shirley, NY, USA) and adminis-
tered without dilution.
Animals and parasites
Experimental monkeys were challenged with parasites
using methods patterned after those described by Schmidt
[18]. Each parasite inoculum contained 1 × 106 Plasmo-
dium cynomolgi bastianellii-parasitized erythrocytes in a
volume of 1.0 mL. Splenectomized P. cynomolgi-naïve rhe-
sus monkeys were used in these experiments. Plasmodium
cynomolgi is fatal to splenectomized rhesus if untreated.
The experiments were performed in 2004.
Study design
Animals were randomly assigned to nine groups: controls
AS 0 mg/kg/day (AS0) plus MB 0 mg/kg/day (MB0) to
which two animals were assigned, and eight experimental
groups to which four animals were assigned. The experi-
mental groups were: AS0 plus either MB 2 mg/kg/day
(MB2) or MB 8 mg/kg/day (MB8); AS 1 mg/kg/day plus
either MB0 (AS1), MB2 (AS1 plus MB2), or MB8 (AS1
plus MB8); AS 8 mg/kg/day plus either MB0 (AS8), MB2
(AS8 plus MB2), or MB8 (AS8 plus MB8). In this way,
evaluations were made of either drug alone at low and
high doses, and the combination of each drug at low and
high doses with the low and high doses of the other drug.
Each dose of drug was administered once a day intraven-
ously for three consecutive days.
Study procedures
There were two cohorts of 17 monkeys each. Each cohort
consisted of one control monkey and two monkeys for
each of the eight treatment groups. Blood smears were
performed daily beginning on the day before the parasite
inoculation until parasitaemia exceeding 5,000 per mm3
were measured. For cohort 1, treatment was initiated
when the cohort’s parasitaemia level reached a mean of
8% on day 9 after parasite inoculation. Because the un-
treated control animal in cohort 1 died one day later,
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taemia reached 5% on day 8 after parasite inoculation.
Treatment was given via a single injection of the desig-
nated drug or immediate sequential injection of the two
drugs in a combination via a peripheral vein once daily for
three consecutive days.
Once treatment was initiated, blood smears were per-
formed every two hours for the first 12 hours after treat-
ment, then every 12 hours at 24, 36, 48, 60, and 72 hours,
then twice daily until parasitaemia cleared, then daily for
four weeks and twice weekly for two weeks and once
weekly for two more weeks.
Endpoints
Parasites were enumerated as per the rat experiments.
Per cent parasitaemia was calculated as per the rat
experiments.
Clearance was defined as being without observable para-
sites for five consecutive days. The parasite clearance time
was defined as the time of the first negative smear. Recru-
descence was defined as the presence of patent parasit-
aemia after clearance. Cure was defined as clearance
without recrudescence by the end of the experiment.
Animal use
Protocols were approved by the WRAIR Institutional Ani-
mal care and Use Committees (IACUC) (rat experiments);
Gorgas Memorial Institute IACUC (Aotus experiments),
and AFRIMS IACUC (Rhesus experiments). Animals wereTable 1 Efficacy of intravenous methylene blue, intravenous
berghei-infected rat
A) Methylene blue alone
Dose (mg/kg/day × 3 days) 0 5 10
Number of rats 6 7 7
Number of rats cleared* 0/6 0/7 0/7
PCT (mean hour)
Mortality (dead/total) 1/6 1/7 0/7
B) Artesunate alone
Dose (mg/kg/day × 3 days) 0 15 30
Number of rats 6 7 6
Number of rats cleared* 0/6 0/7 0/6
PCT (mean hour)
Mortality (dead/total) 1/6 1/7 0/6
C) Methylene blue in combination with artesunate
Dose (mg/kg/day × 3 days) MB5/AS 15 MB10/AS30 MB
Number of rats 8 8 12
Number of rats cleared* 4/8 8/8 12
PCT (mean hour) 61 46 45
Mortality (dead/total) 0/8 0/8 0/1
*Clearance signifies no parasitaemia by day 12 after infection.maintained in accordance with established principles
under the Guide for the Care and Use of Laboratory Ani-
mals [19].
Results
Rats infected with Plasmodium berghei
Control animals
Mean parasitaemia in this group increased to approxi-
mately 5% on day 6, at which point all but the control
animals were treated. In control animals, parasitaemia
rose to approximately 10% on day 8, reached a peak on
day 11 between 10 and 35%, and then declined (self
cleared) to undetectable levels over the next seven to
11 days in the surviving animals. A 16.7% mortality from
malaria was observed in the control rats (Table 1).
Efficacy of intravenous methylene blue alone
No rats administered 5 or 10 mg/kg/day cleared by day
12. All rats administered 20 or 40 mg/kg/day cleared, with
an average clearance time of approximately 50 hours.
Since 80 mg/kg/day was toxic (mortal) to all rats, the
therapeutic index was calculated to be 4.
Efficacy of intravenous artesunate alone
No rats administered 15 or 30 mg/kg/day cleared their
parasites. All rats administered 60, 120 or 240 mg/kg/day
cleared their parasites with an average clearance time of
approximately 50 hours. Since 480 mg/kg/day was toxic to
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Table 2 Aotus experiments
Experiment No 1 methylene blue alone
IV MB dose
(mg/kg/day × 3 days)







Experiment No 2 methylene blue plus artesunate







MB8 plus AS8 3 9
MB8 plus AS8 (Not clear)
MB8 plus AS8 7 9
*Day 1 is the first day of treatment. Day 4 is the first day after three days
of therapy.
**MB4, MB8, AS4, and AS8 signify IV MB 4 mg/kg/day × three days, MB 8 mg/
kg/day × three days, IV AS 4 mg/kg/day × three days, and AS 8 mg/kg/day ×
three days, respectively.
Each row represents data from one animal.
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with intravenous artesunate
Some rats cleared their parasites in each group that re-
ceived combination therapy. Half of the rats in the MB
5 mg/kg/day plus AS 15 mg/kg/day cleared their parasites;
all rats in the MB 10 mg/kg/day plus AS 30 mg/kg/day
group, the MB 20 mg/kg/day plus AS 60 mg/kg/day
group, and the MB 40 mg/kg/day plus AS 120 mg/kg/day
group cleared their parasites. Clearance times were again
close to 50 hours, except for the highest dose group. Since
MB 40 mg/kg/day plus AS 480 mg/kg/day was toxic to all
rats, the therapeutic index was calculated to be between 4
(for MB) and 8 (for AS).
Aotus monkeys infected with Plasmodium falciparum
Control animals
Parasitaemia in all animals increased from approximately
2,000 parasites/mm3 on day 4 after infection to at least
50,000 parasites/mm3 on day 5 after infection, at which
point all but the control animals were treated. By day 8,
the three control monkeys had parasitaemia of 600,000-
800,000 parasites/mm3 and were given rescue therapy.
Experiment No 1: intravenous methylene blue alone
IV MB doses of 8, 16 and 24 mg/kg/day × three days
each cleared 100% of parasites by the fifth day after the
beginning of therapy, although no dose prevented recru-
descence which occurred on days 7–9 (Table 2 top).
Experiment No 2: intravenous methylene blue plus
intravenous artesunate
The purpose of this experiment was to compare malaria
treatment with 8 mg/kg/day IV MB, the lowest dose tested
in experiment No 1 which cleared 100% of parasites in
that experiment, to treatment with 8 mg/kg/day of IV AS
and to the combination of IV AS and IV MB (Table 2
bottom).
As single agents, both drugs cleared 100% of parasites in
each of three animals, although neither drug prevented re-
crudescence on days 7–13. The mean values for clearance
day were approximately equal, although MB delayed re-
crudescence longer than did AS. For the combination of
MB8 plus AS8, one animal did not clear, and the days to
clearance and recrudescence for the two other animals
were not superior to the values for the animals given sin-
gle agents.
Two animals in the AS8 group had haematological ab-
normalities that might be interpreted as due to continued
parasitaemia. One animal had significant thrombocyto-
paenia (<50 × 103 × uL) on day 44 post-therapy. Another
animal had severe anaemia on day 50 post therapy. These
changes in haematologic indices could reflect subpatent
parasitaemia, but if so, parasitaemia did not become pa-
tent by the end of the experiment on day 105. Twoanimals in the MB8/AS8 group had significant loss of
weight or decrease in platelets on days 51 and 56 post
therapy, respectively, but survived to the end of the ex-
periment on day 105 and were considered cured.
Rhesus monkeys infected with Plasmodium cynomolgi
Control animals
The control animal administered AS0 plus MB0 died on
day 1 of ‘therapy’ (cohort 1) or was given rescue therapy
when parasitaemia reached 33% on day 2 of ‘therapy’
(cohort 2) (Table 3).
Drug-treated animals
The efficacy of AS alone, MB alone, or their combination
is shown in Table 3 for each animal. MB2 was relatively
ineffective. Three animals never cleared and the day of
parasite clearance of the animal that did clear was pro-
longed. MB8 was more effective than MB2, since all ani-
mals cleared by day 2 and one did not recrudesce. AS1
caused all animals to clear, although each animal later re-
crudesced. AS8 was more effective than AS1 in the sense
that one of the AS8 animals cured, but one of the AS8 an-
imals died on the first day of therapy of causes unknown.
For the combination groups, clearance times ranged
from two to three days. Although two monkeys in the
Table 3 Rhesus experiment
MB dose* AS dose* Clearance day** Recrudescence day**
or cure
0 0 Died day 1 Not applicable
0 0 Rescued day 2 Not applicable
2 0 Not clear Not applicable
2 0 10 Recrudescence day 12
2 0 Not clear Not applicable
2 0 Not clear Not applicable
8 0 2 Cure
8 0 1 Recrudescence day 12
8 0 1 Recrudescence day 12
8 0 1 Recrudescence day 14
0 1 2 Recrudescence day 11
0 1 3 Recrudescence day 9
0 1 3 Recrudescence day 9
0 1 1 Recrudescence day 7
2 1 1 Cure
2 1 1 Cure
2 1 3 Recrudescence day 5
2 1 1 Recrudescence day 15
8 1 1 Cure
8 1 1 Recrudescence day 15
8 1 4 Cure
8 1 1 Cure
0 8 Died day 2 Not applicable
0 8 1 Cure
0 8 3 Recrudescence day 12
0 8 3 Recrudescence day 11
2 8 Died day 3 Not applicable
2 8 Died day 2 Not applicable
2 8 3 Cure
2 8 3 Cure
8 8 1 Cure
8 8 1 Cure
8 8 1 Cure
8 8 1 Cure
*mg/kg/day × three days.
**Day 1 is the first day of treatment. Day 4 is the first day after three days
of therapy.
Each row represents data from one animal.
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deaths were unlikely due to drug toxicity, since there
were no deaths in the MB8 plus AS8 group. MB8 plus
AS1 therapy was very effective, with all four of four ani-
mals clearing their parasites by day 4 and three of four
animals being cured. The MB8 plus AS8 group wasstrikingly effective, with all four of four animals clearing
parasites by day 1 and all animals being cured.
Discussion
Investigation of IV MB as a potential agent for severe
malaria is driven by the likely impending need for an al-
ternative to or supplementation of IV AS, as artemisinin
resistance spreads beyond Southeast Asia.
IV MB has the advantage of already being approved
worldwide as a treatment for methaemoglobinaemia.
The recommended dose is 1–2 mg/kg repeated once if
necessary, with 7 mg/kg being the ‘prescribing limit’
[20,21]. Other present clinical uses of MB are as a dye to
localize parathyroid tumours prior to surgery, for which
a single dose up to 7.5 mg/kg has been used [22], and to
treat ifosfamide-associated encephalopathy since MB in-
hibits monoamine oxidase conversion of ifosfamide to
an encephalotoxic metabolite [23], for which approxi-
mately 1 mg/kg six times over one day was administered
in one study [24].
Oral MB has already been investigated as a treatment
for uncomplicated malaria. Since the bio-availability of
MB is approximately 70% [10], the MB regimens of 10–
12 mg/kg twice a day for three days that were used in
combination with oral chloroquine, AS or amodiaquine,
are pharmacokinetically equivalent to an intravenous
regimen of 7 mg/kg twice daily for three days. Side ef-
fects in the oral MB plus AS group that were not present
in the amodiaquine-plus-AS group were an increased
frequency of vomiting and dysuria [9]. If the mechanism
of vomiting in response to oral MB is local, treatment
with IV MB would not cause vomiting. A further consid-
eration for the use of IV MB for the severe malaria indi-
cation is that MB may modulate host physiology during
shock. Guanylate cyclase is activated during septic shock
to produce cyclic guanosine monophosphate, which in
turn leads to relaxation of myocardial and vascular smooth
muscle and an increase in vascular permeability. MB is an
inhibitor of guanylate cyclase and thus could lead to vaso-
constrictive and positive inotropic effects during shock
states [25]. Another possible concern is the generation of
methaemoglobin from haemoglobin, which, for example,
equaled 5% when one patient was administered 7 mg/kg in
a case report [26]. In this regard, severe malaria patients
treated with artesunate sometimes experience a delayed
hemolytic episode [27]. It is not likely that there would be
pharmacokinetic interactions between AS and MB. Artesu-
nate is converted in vivo to dihydroartemisinin [28], which
is glucuronidated in the liver [29]. Methylene blue is rap-
idly reduced to leucomethylene blue in tissues [21].
Based on the hypothesis that IV MB at a dose of 7 mg/kg
either daily or twice daily for three days might have utility
for severe malaria as a replacement for, or in combination
with, IV AS, IV MB was evaluated in rat and non-human
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the approximate length of time that intravenous drugs are
administered in the initial treatment of severe malaria in
humans.
In rats infected with P. berghei, the minimal dose of IV
MB that cleared parasites from all animals was 20 mg/kg/
day and the minimal dose of IV AS that cleared parasites
from all animals was 60 mg/kg/day. Although this com-
parison suggests that MB is superior to AS, the 100% toxic
doses of these drugs were 80 mg/kg/day (MB) vs 480 mg/
kg/day (AS) and thus AS had a superior therapeutic index.
The combination of MB plus AS was more effective than
either drug alone, since MB 10 mg/kg/day plus AS 30 mg/
kg/day cleared all parasites. The implication that MB plus
an artemisinin is more effective in rodents than either
drug alone is consistent with a recent brief report of a
mouse model. In C57BL6/N mice infected with P. berghei,
five days of intraperitoneal treatment with MB (10 mg/kg)
or dihydroartemisinin (3 mg/kg) permitted survival only
to 9 days or 25 days, respectively, but the combination
permitted survival of 80% of animals through 45 days [30].
In Aotus infected with P. falciparum, IV MB at 24 mg/
kg/day, 16 mg/kg/day and 8 mg/kg/day cleared parasites
by two days after the end of therapy. In the subsequent
Aotus experiment, IV MB at the lowest previously tested
dose (8 mg/kg/day) was compared to IV AS at the same
dose. For both MB and AS, all monkeys cleared by three
days after the end of therapy, although each monkey re-
crudesced soon thereafter. The combination of both drugs
at a dose of 8 mg/kg/day in this model did not result in ef-
ficacy data that were superior to either drug alone.
In rhesus infected with blood stages of P. cynomolgi, IV
MB and IV AS were tested at a low dose (2 mg/kg/day for
IV MB, 1 mg/kg/day for IV AS) and at a high dose of
8 mg/kg/day, alone and in combination. At the lower
doses, AS was superior to MB in terms of clearance, since
all of the AS animals cleared but three of the four MB-
treated animals did not. At 8 mg/kg/day, IV MB and IV
AS performed comparably: parasite clearance occurred by
day 3 of therapy, except for one AS animal that died dur-
ing treatment.
A high dose of MB (8 mg/kg/day) plus a low dose of
AS (1 mg/kg/day) appeared more effective than either
drug alone: three of four animals cured. A high dose of
AS (8 mg/kg/day) plus a low dose of MB (2 mg/kg/day)
also appeared effective (two of four animals cured) al-
though two animals died during treatment for unknown
reasons. The combination of high doses of MB and AS
(8 mg/kg/day for each drug) was 100% successful: all
four of four animals cured.
Overall, the efficacy of MB was approximately equal to
that of standard of care AS in each of the three animal
models. In two of the models, rat and rhesus, the com-
bination was more effective than either agent alone. Thecomparable efficacy of IV MB to IV AS, and the high cure
rate of the high dose of MB plus either the low dose of AS
or the full dose of AS, in splenectomized rhesus is note-
worthy given that this is a non-human primate model for
which untreated infections are fatal.
These data suggest that IV MB and combinations of
IV MB and IV AS have potential for malaria treatment.
Further investigation might be undertaken in a non-
human-primate model of cerebral malaria, the Plasmo-
dium coatneyi-infected rhesus monkey [31]. Additionally,
since both IV MB and IV AS are clinical agents, IV MB
alone and in combination with IV AS might be evaluated
in progressively more severe cases of clinical malaria.
Conclusion
IV MB, an approved clinical agent, was approximately as
effective as IV AS, the standard of care for severe mal-
aria, in preclinical rat and non-human primate models.
The combination of both drugs was more effective than
either drug alone in the P. cynomolgi-infected rhesus
monkey, for which untreated infections are fatal. This
large preclinical experience suggests that IV MB, alone
or in combination with IV AS, be evaluated in preclinical
models of severe malaria and potentially in clinical se-
vere malaria.
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